Humankind Investments’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-6,452
Closed -$1.23M 64
2025
Q3
$1.23M Buy
6,452
+233
+4% +$41.3K 0.28% 45
2025
Q2
$1.12M Buy
6,219
+571
+10% +$99.2K 0.27% 48
2025
Q1
$956K Sell
5,648
-280
-5% -$46K 0.25% 58
2024
Q4
$894K Sell
5,928
-94
-2% -$14.6K 0.23% 60
2024
Q3
$935K Sell
6,022
-17
-0.3% -$2.54K 0.34% 50
2024
Q2
$827K Buy
6,039
+1,008
+20% +$138K 0.22% 59
2024
Q1
$670K Buy
5,031
+730
+17% +$94.7K 0.18% 65
2023
Q4
$593K Sell
4,301
-80
-2% -$10.5K 0.18% 67
2023
Q3
$534K Sell
4,381
-96
-2% -$12.8K 0.22% 59
2023
Q2
$629K Buy
4,477
+202
+5% +$27.8K 0.25% 54
2023
Q1
$605K Sell
4,275
-92
-2% -$13.2K 0.25% 62
2022
Q4
$683K Sell
4,367
-308
-7% -$44.3K 0.3% 56
2022
Q3
$574K Buy
4,675
+946
+25% +$125K 0.28% 59
2022
Q2
$496K Sell
3,729
-1,280
-26% -$174K 0.24% 63
2022
Q1
$686K Buy
5,009
+792
+19% +$110K 0.28% 45
2021
Q4
$730K Buy
4,217
+503
+14% +$76.5K 0.92% 34
2021
Q3
$540K Sell
3,714
-122
-3% -$17.9K 0.82% 39
2021
Q2
$506K Buy
3,836
+1,259
+49% +$165K 0.9% 39
2021
Q1
$331K Buy
+2,577
New +$318K 1.02% 38

Other funds holding DGX

Humankind Investments's DGX Position: Q4 2025 in Review

Humankind Investments sold out of Quest Diagnostics (DGX) in Q4 2025, closing a stake of 6,452 shares — an estimated $1.23M sold.

Humankind Investments first reported a position in DGX in Q1 2021 and held it in 19 quarters. The position peaked at $1.23M in Q3 2025. 1,048 funds tracked by Wall St. Rank hold DGX as of Q4 2025.

  • Humankind Investments reported no remaining Quest Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Humankind Investments sold 6,452 Quest Diagnostics shares in Q4 2025, an estimated $1.23M.
  • Humankind Investments first reported a position in Quest Diagnostics in Q1 2021 and held it in 19 quarters.
  • Humankind Investments's Quest Diagnostics position peaked at $1.23M in Q3 2025.
  • 1,048 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.

Based on Humankind Investments's 13F filing for Q4 2025, filed 17 Feb 2026.